Business Context and Reporting Period
This Form 8-K was filed by NanoVibronix, Inc. (not Envue Medical, Inc.) on March 23, 2017. The report details a material definitive agreement involving a bridge financing transaction completed on the same date.
Key Financial Metrics
- Financing Amount: $100,000 principal received via a convertible promissory note.
- Interest Rate: 6% per annum on the note.
- Warrant Issuance: 40,000 shares of common stock at an exercise price of $5.90 per share.
- Debt Maturity: The earlier of 5 years from issuance or the completion of a "Qualified Financing" (equity raise of at least $2,000,000).
- Liquidity Impact: Immediate cash inflow of $100,000.
Material Changes
The filing represents a new direct financial obligation and the issuance of unregistered equity securities. The company entered into a bridge financing agreement with an accredited investor, creating a convertible debt instrument and associated warrants. No prior period financial data is provided in this specific filing for comparison.
Guidance, Outlook, and Risks
- Conversion Mechanics: Upon maturity or a Qualified Financing, the investor may convert the note into equity at a discount (80% of the fair value or financing price) or a fixed price of $5.90, whichever is lower.
- Change of Control: In the event of a change of control, the investor has the option to receive cash or convert the note into equity immediately prior to the transaction closing.
- Warrant Restrictions: Warrants are immediately exercisable but subject to a 9.99% beneficial ownership limitation. Cashless exercise is permitted if no registration statement is effective after six months.
- Regulatory Status: The securities were issued under Section 4(a)(2) and Rule 506 of Regulation D exemptions.
Investor Verification Checklist
- Verify the company's current cash position and runway following the $100,000 infusion.
- Confirm the status of any ongoing efforts to secure a "Qualified Financing" of $2,000,000 to trigger early note conversion.
- Review the full text of Exhibits 10.1 (Note) and 10.2 (Warrant) for specific adjustment formulas regarding stock splits or dividends.
- Assess the potential dilution impact of the 40,000 warrant shares and the potential conversion of the $100,000 note at the 80% discount rate.